Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/42067
Title: Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC)
Authors: RAFII, HanadiGARNIER, FedericoRUGGERI, AnnalisaIONESCU, IrinaBALLOT, CarolineBENSOUSSAN, DanieleCHABANNON, ChristianDAZEY, BernardVOS, John DeGAUTIER, EricGIRAUD, ChristineLARGHERO, JeromeCRAS, AudreyMIALOU, ValeriePERSOONS, VirginiePOUTHIER, FabienneTHIBERT, Jean-BaptisteDALLE, Jean-HuguesMICHEL, GerardKENZEY, ChantalVOLT, FernandaROCHA, VandersonBAY, Jacques-OlivierRUBIO, Marie-ThereseFAUCHER, CatherineMARRY, EvelyneGLUCKMAN, Eliane
Citation: BONE MARROW TRANSPLANTATION, v.56, n.10, p.2497-2509, 2021
Abstract: The public French Cord Blood Banks Network was established in 1999 with the objective of standardizing the practices governing umbilical cord blood (UCB) banking in France. The Network adopted a strategy to optimize its inventory and improve the quality of its banked units based on a quality improvement process using outcome data regularly provided by Eurocord. This study aimed to describe the results, over 10 years, of UCBT facilitated by a national network that used the same criteria of UCB collection and banking and to assess how modifications of banking criteria and unit selection might influence transplant outcomes. Nine hundred and ninety-nine units (593 single-unit and 203 double-unit grafts) were released by the Network to transplant 796 patients with malignant (83%) and non-malignant (17%) diseases. Median cell dose exceeded 3.5 x 10(7) TNC/kg in 86%. There was a trend to select units more recently collected and with higher cell dose. Neutrophil engraftment was 88.2% (85.7-90.7) and 79.3% (72.6-86.5) respectively for malignant and non-malignant diseases with a trend to faster recovery with higher cell doses. The respective 3-year transplant-related mortality were 31.1% (27.5-35.1) and 34.3% (27.0-43.5). OS was 49% +/- 4 in malignant and 62% +/- 4 in non-malignant disorders. In multivariate analysis, cell dose was the only unit-related factor associated with outcomes. Our results reflect the benefit on clinical outcomes of the strategy adopted by the Network to bank units with higher cell counts.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/31
LIM/31 - Laboratório de Genética e Hematologia Molecular

Artigos e Materiais de Revistas Científicas - ODS/10
ODS/10 - Redução da desigualdade


Files in This Item:
File Description SizeFormat 
art_RAFII_Umbilical_cord_blood_transplants_facilitated_by_the_French_2021.PDF
  Restricted Access
publishedVersion (English)1.07 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.